Li Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Li Feng has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Fan Li
Endoscopy Center, Minhang Hospital, Fudan University, Shanghai, China
12 shared publicationsXiaohong Zhang
Endoscopy Center, Minhang Hospital, Fudan University, Shanghai, China
12 shared publicationsSonghua Bei
Endoscopy Center, Minhang Hospital, Fudan University, Shanghai, China
11 shared publicationsJian Li
Endoscopy Center, Minhang Hospital, Fudan University, Shanghai, China
10 shared publicationsFangzhou Ye
Endoscopy Center, Minhang Hospital, Fudan University, Shanghai, China
8 shared publicationsJun Jiang
Endoscopy Center, Minhang Hospital, Fudan University, Shanghai, China
8 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
STC2 promotes colorectal cancer progression via c-Myc-mediated glycolysis and the PI3K/AKT/mTOR pathway
Background While growing evidence highlights the significance of metabolic reprogramming in colorectal cancer (CRC), the exact mechanisms behind these changes remain unclear. This study sought to identify key metabolic regulators and clarify their downstream pathways in CRC progression. Methods Three independent CRC datasets were subjected to differential expression analysis and lactylation-related gene screening, resulting in candidate genes, among which the STC2 gene was prioritized. STC2 expression was first assessed in HIEC-6, Caco-2, LoVo, SW480, and HCT116 cells. STC2 knockdown and overexpression models were established in HCT116 cells to examine their effects on proliferation, migration, invasion, and apoptosis. Lactate production and glucose uptake tests, Western blot, chromatin immunoprecipitation (ChIP), and Quantitative real-time polymerase chain reaction (qRT-PCR) were utilized to delineate the molecular mechanisms. A xenograft mouse model was applied to validate in vivo effects. Results STC2 levels in CRC cells are significantly higher than in normal intestinal cells. STC2 knockdown inhibits cell growth and glycolysis, but its overexpression significantly enhances these activities. Mechanistically, STC2 enhanced c-Myc activity through the PI3K/AKT/mTOR pathway, which upregulated GLUT1 and LDHA to maintain glycolytic flux. ChIP analysis showed that c-Myc occupancy on the GLUT1 and LDHA promoters was increased under STC2 overexpression, whereas binding was reduced upon STC2 silencing. In vivo, STC2 overexpression accelerated tumor growth and enhanced glycolysis in a xenograft mouse model. Conclusion These findings highlight STC2 as a key regulator of CRC progression, which regulates c-Myc-driven glycolysis through the PI3K/AKT/mTOR pathway. Targeting STC2 or its downstream metabolic effectors may provide new therapeutic strategies for CRC management.
- 17 March 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessSTC2 promotes colorectal cancer progression via c-Myc-mediated glycolysis and the PI3K/AKT/mTOR pathway
Background While growing evidence highlights the significance of metabolic reprogramming in colorectal cancer (CRC), the exact mechanisms behind these changes remain unclear. This study sought to identify key metabolic regulators and clarify their downstream pathways in CRC progression. Methods Three independent CRC datasets were subjected to differential expression analysis and lactylation-related gene screening, resulting in candidate genes, among which the STC2 gene was prioritized. STC2 expression was first assessed in HIEC-6, Caco-2, LoVo, SW480, and HCT116 cells. STC2 knockdown and overexpression models were established in HCT116 cells to examine their effects on proliferation, migration, invasion, and apoptosis. Lactate production and glucose uptake tests, Western blot, chromatin immunoprecipitation (ChIP), and Quantitative real-time polymerase chain reaction (qRT-PCR) were utilized to delineate the molecular mechanisms. A xenograft mouse model was applied to validate in vivo effects. Results STC2 levels in CRC cells are significantly higher than in normal intestinal cells. STC2 knockdown inhibits cell growth and glycolysis, but its overexpression significantly enhances these activities. Mechanistically, STC2 enhanced c-Myc activity through the PI3K/AKT/mTOR pathway, which upregulated GLUT1 and LDHA to maintain glycolytic flux. ChIP analysis showed that c-Myc occupancy on the GLUT1 and LDHA promoters was increased under STC2 overexpression, whereas binding was reduced upon STC2 silencing. In vivo, STC2 overexpression accelerated tumor growth and enhanced glycolysis in a xenograft mouse model. Conclusion These findings highlight STC2 as a key regulator of CRC progression, which regulates c-Myc-driven glycolysis through the PI3K/AKT/mTOR pathway. Targeting STC2 or its downstream metabolic effectors may provide new therapeutic strategies for CRC management.
- Open Access
- 16 March 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Regulation of natural killer cell infiltration and tumor progression by CMTM6 in gastric cancer
Tumor CMTM6 is known to regulate programmed death-ligand 1 expression and affect the cytotoxicity of infiltrating T cells, while its impact on natural kill
- 16 March 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessRegulation of natural killer cell infiltration and tumor progression by CMTM6 in gastric cancer
Tumor CMTM6 is known to regulate programmed death-ligand 1 expression and affect the cytotoxicity of infiltrating T cells, while its impact on natural kill
- Open Access
- 28 January 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
RHOJ derived peptide promotes chemosensitivity by inhibiting glutamine metabolism in gastric cancer
Chemoresistance is a cause of chemotherapy failure in gastric cancer (GC) treatment. Recent studies have shown that the dysregulation of glutamine metaboli
- 28 January 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessRHOJ derived peptide promotes chemosensitivity by inhibiting glutamine metabolism in gastric cancer
Chemoresistance is a cause of chemotherapy failure in gastric cancer (GC) treatment. Recent studies have shown that the dysregulation of glutamine metaboli
- Open Access
- 1 January 2026
- Published by Tech Science Press in Oncology Research
- Vol. 34 (5) , 1-10
CDCA7 Promotes Proliferation and Suppresses Apoptosis in Gastric Cancer via HELLS-Mediated Chromatin Remodeling
Background: In various tumor types, cell division cycle-associated 7 (CDCA7) is involved in chromatin remodeling and DNA methylation. However, its biological functions and regulatory mechanisms in gastric cancer (GC) remain unknown. This investigation intended to identify the function of CDCA7 in GC progression and elucidate its epigenetic regulatory mechanisms. Methods: Differentially expressed genes (DEGs) were detected from the GSE19826, TCGA-GC, and GSE56807 datasets. Networks of protein-protein interactions (PPI) and hub genes were discovered by the DMNC and Clustering Coefficient algorithms. Receiver operating characteristic (ROC) analysis and expression profiling were undertaken to determine diagnostic performance. In vitro assays, including CCK-8 assays, clonogenic assays, flow cytometry, dot blots, co-immunoprecipitation (Co-IP), chromatin immunoprecipitation (ChIP), and Western blots, were applied to evaluate the role of CDCA7 and its interaction with helicase, lymphoid-specific (HELLS). Results: 169 overlapping genes were discovered, enriched in Cell adhesion molecules and ECM-receptor interaction. CDCA7 is highly expressed in GC and has high clinical diagnostic value. Knockdown of CDCA7 causes apoptosis and suppresses GC cell invasion, migration, and proliferation. Mechanistically, CDCA7 physically interacts with HELLS and promotes HELLS recruitment to chromatin. Knockdown of CDCA7 reduces global 5 hmC/5 mC levels and histone methylation (H3K9me3 and H4K20me3), while HELLS overexpression partially reverses these effects. Functionally, HELLS overexpression also partially reverses the antiproliferative and proapoptotic effects of CDCA7 knockdown. Conclusion: CDCA7 promotes GC progression by interacting with HELLS to regulate DNA methylation and chromatin stability, suggesting that the CDCA7-HELLS axis may serve as a potential diagnostic biomarker and therapeutic target for GC.
- 1 January 2026
- Published by Tech Science Press in Oncology Research
- Vol. 34 (5) , 1-10
Open AccessCDCA7 Promotes Proliferation and Suppresses Apoptosis in Gastric Cancer via HELLS-Mediated Chromatin Remodeling
Background: In various tumor types, cell division cycle-associated 7 (CDCA7) is involved in chromatin remodeling and DNA methylation. However, its biological functions and regulatory mechanisms in gastric cancer (GC) remain unknown. This investigation intended to identify the function of CDCA7 in GC progression and elucidate its epigenetic regulatory mechanisms. Methods: Differentially expressed genes (DEGs) were detected from the GSE19826, TCGA-GC, and GSE56807 datasets. Networks of protein-protein interactions (PPI) and hub genes were discovered by the DMNC and Clustering Coefficient algorithms. Receiver operating characteristic (ROC) analysis and expression profiling were undertaken to determine diagnostic performance. In vitro assays, including CCK-8 assays, clonogenic assays, flow cytometry, dot blots, co-immunoprecipitation (Co-IP), chromatin immunoprecipitation (ChIP), and Western blots, were applied to evaluate the role of CDCA7 and its interaction with helicase, lymphoid-specific (HELLS). Results: 169 overlapping genes were discovered, enriched in Cell adhesion molecules and ECM-receptor interaction. CDCA7 is highly expressed in GC and has high clinical diagnostic value. Knockdown of CDCA7 causes apoptosis and suppresses GC cell invasion, migration, and proliferation. Mechanistically, CDCA7 physically interacts with HELLS and promotes HELLS recruitment to chromatin. Knockdown of CDCA7 reduces global 5 hmC/5 mC levels and histone methylation (H3K9me3 and H4K20me3), while HELLS overexpression partially reverses these effects. Functionally, HELLS overexpression also partially reverses the antiproliferative and proapoptotic effects of CDCA7 knockdown. Conclusion: CDCA7 promotes GC progression by interacting with HELLS to regulate DNA methylation and chromatin stability, suggesting that the CDCA7-HELLS axis may serve as a potential diagnostic biomarker and therapeutic target for GC.
- 31 December 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 799, 153177
Targeting SLC7A11 sensitizes colorectal cancer cells to elesclomol–Cu–induced cuproptosis via the GSH-GPX4 axis
- 31 December 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 799, 153177
Targeting SLC7A11 sensitizes colorectal cancer cells to elesclomol–Cu–induced cuproptosis via the GSH-GPX4 axis
- 5 September 2025
- Published by Wiley in Drug Development Research
- Vol. 86 (6) , e70151
Theaflavins Inhibit Proliferation and Glycolysis of Colorectal Cancer Cells by Downregulating DDIT4
Colorectal cancer (CRC) is a common malignancy often characterized by metastasis and poor prognosis. This study attempts to ascertain the anticancer impacts of theaflavin (TF) on CRC cells and examine the fundamental molecular mechanisms, focusing on the function of DDIT4 in CRC progression. This study utilized RNA sequencing for gene expression profiling, differential expression analysis, and Venn diagram analysis for overlapping genes. Protein interactions were explored, while cell viability was evaluated using colony formation assays and Cell Counting Kit‐8 (CCK‐8). Flow cytometry was employed for apoptosis analysis, and Transwell assays measured cell migration and invasion. ATP synthesis, lactate production, and glucose uptake were analyzed to evaluate metabolic changes, with protein and RNA expression identified by Western blot and quantitative real‐time polymerase chain reaction (qRT‐PCR). This study reveals that TF effectively inhibits CRC cell invasion, migration, and proliferation in a dose‐ and time‐dependent manner. TF induces apoptosis by suppressing the antiapoptotic protein Bcl‐2 and enhancing proapoptotic proteins (Cleaved Caspase‐3, Bax, and Caspase‐9). Through bioinformatics analysis, DDIT4 was identified as a key target gene. Additionally, correlation analysis highlighted a positive relationship between DDIT4 and the glycolysis/gluconeogenesis pathway. TF downregulates DDIT4 expression, which suppresses CRC cell proliferation and glycolysis. Moreover, DDIT4 overexpression partially reverses the suppressive impacts of TF on glycolysis and cell viability. These observations imply that TF suppresses CRC progression by targeting DDIT4 and regulating glycolytic activity, highlighting its promise as a medicinal substance for the treatment of CRC.
- 5 September 2025
- Published by Wiley in Drug Development Research
- Vol. 86 (6) , e70151
Theaflavins Inhibit Proliferation and Glycolysis of Colorectal Cancer Cells by Downregulating DDIT4
Colorectal cancer (CRC) is a common malignancy often characterized by metastasis and poor prognosis. This study attempts to ascertain the anticancer impacts of theaflavin (TF) on CRC cells and examine the fundamental molecular mechanisms, focusing on the function of DDIT4 in CRC progression. This study utilized RNA sequencing for gene expression profiling, differential expression analysis, and Venn diagram analysis for overlapping genes. Protein interactions were explored, while cell viability was evaluated using colony formation assays and Cell Counting Kit‐8 (CCK‐8). Flow cytometry was employed for apoptosis analysis, and Transwell assays measured cell migration and invasion. ATP synthesis, lactate production, and glucose uptake were analyzed to evaluate metabolic changes, with protein and RNA expression identified by Western blot and quantitative real‐time polymerase chain reaction (qRT‐PCR). This study reveals that TF effectively inhibits CRC cell invasion, migration, and proliferation in a dose‐ and time‐dependent manner. TF induces apoptosis by suppressing the antiapoptotic protein Bcl‐2 and enhancing proapoptotic proteins (Cleaved Caspase‐3, Bax, and Caspase‐9). Through bioinformatics analysis, DDIT4 was identified as a key target gene. Additionally, correlation analysis highlighted a positive relationship between DDIT4 and the glycolysis/gluconeogenesis pathway. TF downregulates DDIT4 expression, which suppresses CRC cell proliferation and glycolysis. Moreover, DDIT4 overexpression partially reverses the suppressive impacts of TF on glycolysis and cell viability. These observations imply that TF suppresses CRC progression by targeting DDIT4 and regulating glycolytic activity, highlighting its promise as a medicinal substance for the treatment of CRC.
- Open Access
- 1 August 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (8) , 6151-6162
Alleviation of exercise-induced injury by hydrogen inhalation via the reduction of oxidative stress and inflammation in athletes
Background: Strenuous exercise can lead to exercise-induced lung injury, primarily driven by elevated oxidative stress and systemic inflammation. Although hydrogen (H2) inhalation has been proposed as a nonpharmacological intervention with antioxidant and anti-inflammatory potential, its effects in the context of exercise remain poorly understood. This study aimed to investigate whether H2 inhalation could mitigate exercise-induced systemic stress responses in athletes. Methods: Thirty-one healthy athletes were divided into a control group (n=14), an infrared blanket group (n=9), and a H2 inhalation group (n=8). Blood samples were collected before and after winter training to evaluate oxidative stress [total antioxidant capacity (T-AOC), superoxide dismutase (SOD), and malondialdehyde (MDA)], inflammation and lung injury-related markers [white blood cell count (WBC)], C-reactive protein (CRP), hematological indicators [red blood cell count (RBC), hemoglobin (HB), hematocrit (HCT), and mean corpuscular volume (MCV)], biochemical indicators [creatine kinase (CK) and blood urea nitrogen (BUN)], and stress-related hormones [total cholesterol (T), cholesterol (C), and ferritin (FE)]. Lung injury was considered to reflect exercise-induced lung stress. The systemic and inflammatory indices of stimulation were inferred. Results: After a single postexercise intervention, the H2 group showed improved antioxidant capacity and reduced WBC and CRP levels. These effects persisted after winter training. Moreover, the H2 group maintained stable RBC, HB, and HCT levels, unlike the infrared blanket group, suggesting better preservation of oxygen-carrying capacity and hematological stability. Conclusions: H2 inhalation attenuates exercise-induced lung injury by reducing oxidative stress and inflammation. It may represent a promising adjunctive approach for protecting pulmonary function during intensive athletic training in the winter.
- 1 August 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (8) , 6151-6162
Open AccessAlleviation of exercise-induced injury by hydrogen inhalation via the reduction of oxidative stress and inflammation in athletes
Background: Strenuous exercise can lead to exercise-induced lung injury, primarily driven by elevated oxidative stress and systemic inflammation. Although hydrogen (H2) inhalation has been proposed as a nonpharmacological intervention with antioxidant and anti-inflammatory potential, its effects in the context of exercise remain poorly understood. This study aimed to investigate whether H2 inhalation could mitigate exercise-induced systemic stress responses in athletes. Methods: Thirty-one healthy athletes were divided into a control group (n=14), an infrared blanket group (n=9), and a H2 inhalation group (n=8). Blood samples were collected before and after winter training to evaluate oxidative stress [total antioxidant capacity (T-AOC), superoxide dismutase (SOD), and malondialdehyde (MDA)], inflammation and lung injury-related markers [white blood cell count (WBC)], C-reactive protein (CRP), hematological indicators [red blood cell count (RBC), hemoglobin (HB), hematocrit (HCT), and mean corpuscular volume (MCV)], biochemical indicators [creatine kinase (CK) and blood urea nitrogen (BUN)], and stress-related hormones [total cholesterol (T), cholesterol (C), and ferritin (FE)]. Lung injury was considered to reflect exercise-induced lung stress. The systemic and inflammatory indices of stimulation were inferred. Results: After a single postexercise intervention, the H2 group showed improved antioxidant capacity and reduced WBC and CRP levels. These effects persisted after winter training. Moreover, the H2 group maintained stable RBC, HB, and HCT levels, unlike the infrared blanket group, suggesting better preservation of oxygen-carrying capacity and hematological stability. Conclusions: H2 inhalation attenuates exercise-induced lung injury by reducing oxidative stress and inflammation. It may represent a promising adjunctive approach for protecting pulmonary function during intensive athletic training in the winter.
- Open Access
- 23 June 2025
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 22 (12) , 3053-3069
Ginsenoside Rh7 affects β-catenin nuclear translocation by inhibiting SHCBP1 expression, thereby inhibiting epithelial-mesenchymal transition in gastric cancer cells
Background: Ginsenoside Rh7 is a bioactive compound with anticancer properties. This investigation was conducted to analyze the anticancer effects of ginsenoside Rh7 and its underlying molecular mechanisms in gastric cancer (GC) cells.
- 23 June 2025
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 22 (12) , 3053-3069
Open AccessGinsenoside Rh7 affects β-catenin nuclear translocation by inhibiting SHCBP1 expression, thereby inhibiting epithelial-mesenchymal transition in gastric cancer cells
Background: Ginsenoside Rh7 is a bioactive compound with anticancer properties. This investigation was conducted to analyze the anticancer effects of ginsenoside Rh7 and its underlying molecular mechanisms in gastric cancer (GC) cells.
- Open Access
- 22 May 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (6) , 1525-1535
Global Epidemiology of Early‐Onset Digestive System Malignancy: A Systematic Analysis for the Global Burden of Disease Study 2021
Background and Aim: The researches on the global burden of digestive system malignancy in young populations were limited. This study aimed to comprehensively investigate the burden of early‐onset digestive system malignancy (often defined as cancers diagnosed below the age of 50) based on the Global Burden of Disease 2021.Methods: Data of incidence, prevalence, deaths, disability‐adjusted life years (DALYs), and risk factors for the five major early‐onset digestive system malignancies, including early‐onset esophageal cancer (EOEC), early‐onset gastric cancer (EOGC), early‐onset liver cancer (EOLC), early‐onset pancreatic cancer (EOPC), and early‐onset colorectal cancer (EOCRC), were extracted from GBD 2021. The average annual percent change (AAPC) was calculated using joinpoint regression analysis. The Bayesian age–period–cohort (BAPC) model was utilized to predict the burden up to 2030.Results: From 1990 to 2021, the age‐standardized incidence rate (ASIR) of early‐onset digestive system malignancies, except for EOCRC (AAPC, 0.37), showed a decreasing pattern. Meanwhile, the age‐standardized mortality rate (ASMR) and age‐standardized DALYs rate (ASDR) of early‐onset digestive system malignancy presented a downward trend. Notably, high‐middle sociodemographic index (SDI) countries experienced higher disease burdens. Dietary risk factors, tobacco, alcohol consumption, and metabolic factors were the main risk factors. The ASIR of EOEC and EOCRC was projected to increase in 2030, whereas the trend for EOGC, EOLC, and EOPC was projected to decrease.Conclusions: Early‐onset digestive system malignancy presented notable heterogeneity across gender, geography, and cancer types. This emphasizes the urgency of addressing the public health challenge of early‐onset digestive system malignancy.
- 22 May 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (6) , 1525-1535
Open AccessGlobal Epidemiology of Early‐Onset Digestive System Malignancy: A Systematic Analysis for the Global Burden of Disease Study 2021
Background and Aim: The researches on the global burden of digestive system malignancy in young populations were limited. This study aimed to comprehensively investigate the burden of early‐onset digestive system malignancy (often defined as cancers diagnosed below the age of 50) based on the Global Burden of Disease 2021.Methods: Data of incidence, prevalence, deaths, disability‐adjusted life years (DALYs), and risk factors for the five major early‐onset digestive system malignancies, including early‐onset esophageal cancer (EOEC), early‐onset gastric cancer (EOGC), early‐onset liver cancer (EOLC), early‐onset pancreatic cancer (EOPC), and early‐onset colorectal cancer (EOCRC), were extracted from GBD 2021. The average annual percent change (AAPC) was calculated using joinpoint regression analysis. The Bayesian age–period–cohort (BAPC) model was utilized to predict the burden up to 2030.Results: From 1990 to 2021, the age‐standardized incidence rate (ASIR) of early‐onset digestive system malignancies, except for EOCRC (AAPC, 0.37), showed a decreasing pattern. Meanwhile, the age‐standardized mortality rate (ASMR) and age‐standardized DALYs rate (ASDR) of early‐onset digestive system malignancy presented a downward trend. Notably, high‐middle sociodemographic index (SDI) countries experienced higher disease burdens. Dietary risk factors, tobacco, alcohol consumption, and metabolic factors were the main risk factors. The ASIR of EOEC and EOCRC was projected to increase in 2030, whereas the trend for EOGC, EOLC, and EOPC was projected to decrease.Conclusions: Early‐onset digestive system malignancy presented notable heterogeneity across gender, geography, and cancer types. This emphasizes the urgency of addressing the public health challenge of early‐onset digestive system malignancy.